Javascript must be enabled to continue!
In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom
View through CrossRef
Abstract
The monocled cobra (
Naja kaouthia
) is one of the most feared snakes in Southeast Asia. It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain α-neurotoxins. The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies. Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques. Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against α-cobratoxin using phage display technology. Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in
in vitro
neutralization potency and
in vivo
efficacy. While the parental antibody prolonged survival of mice challenged with purified α-cobratoxin, the optimized antibody prevented lethality when incubated with
N. kaouthia
whole venom prior to intravenous injection. This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody. Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of
N. kaouthia
, as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic.
One Sentence Summary
A recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using
in vitro
methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of α-neurotoxin-mediated neurotoxicity.
openRxiv
Line Ledsgaard
Andreas H. Laustsen
Urska Pus
Jack Wade
Pedro Villar
Kim Boddum
Peter Slavny
Edward W. Masters
Ana S. Arias
Saioa Oscoz
Daniel T. Griffiths
Alice M. Luther
Majken Lindholm
Rachael A. Leah
Marie Sofie Møller
Hanif Ali
John McCafferty
Bruno Lomonte
José M. Gutiérrez
Aneesh Karatt-Vellatt
Title: In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom
Description:
Abstract
The monocled cobra (
Naja kaouthia
) is one of the most feared snakes in Southeast Asia.
It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain α-neurotoxins.
The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies.
Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques.
Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against α-cobratoxin using phage display technology.
Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in
in vitro
neutralization potency and
in vivo
efficacy.
While the parental antibody prolonged survival of mice challenged with purified α-cobratoxin, the optimized antibody prevented lethality when incubated with
N.
kaouthia
whole venom prior to intravenous injection.
This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody.
Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of
N.
kaouthia
, as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic.
One Sentence Summary
A recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using
in vitro
methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of α-neurotoxin-mediated neurotoxicity.
Related Results
Studies on physiological effects, toxinokinetics and biological characteristics of the venom of Bungarus candidus from different parts of Thailand
Studies on physiological effects, toxinokinetics and biological characteristics of the venom of Bungarus candidus from different parts of Thailand
The studies in four groups of Bungarus candidus from northeastern, southern and eastern Thailand, and captive born group were carried out. The determinations of morphology of Bunga...
Cobra Venom Factor: Evidence for Its Being Altered Cobra C3 (the Third Component of Complement)
Cobra Venom Factor: Evidence for Its Being Altered Cobra C3 (the Third Component of Complement)
Evidence is presented that cobra venom factor, the anticomplementary protein in
Naja naja
venom, is modified cobra C3 (the third component of complement). A...
Integrative multi-omics analysis reveals the contribution of neoVTX genes to venom diversity of Synanceia verrucosa
Integrative multi-omics analysis reveals the contribution of neoVTX genes to venom diversity of Synanceia verrucosa
Abstract
Background
Animal venom systems have been considered as valuable model for investigating molecular mechanisms underlying phenotypic evolution. The stonefish were ...
Medicinal potentials of snake venom components: A review
Medicinal potentials of snake venom components: A review
Over the last several decades, research on snake venom toxins has provided not only new tools to decipher molecular details of various physiological processes, but also inspiration...
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals
The animal kingdom, particularly reptiles, is widely recognized as a valuable source of peptides and proteins with applications in medicine, the pharmaceutical industry and, more r...
EVALUATION OF BARU (DIPTERYX ALATA) FLOUR AS A POTENTIAL INHIBITOR OF THE LACHESIS MUTA MUTA SNAKE VENOM -INDUCED MYOTOXICITY AND NEUROMUSCULAR BLOCKADE
EVALUATION OF BARU (DIPTERYX ALATA) FLOUR AS A POTENTIAL INHIBITOR OF THE LACHESIS MUTA MUTA SNAKE VENOM -INDUCED MYOTOXICITY AND NEUROMUSCULAR BLOCKADE
Snake venom is a complex mixture of bioactive substances known to induce a wide range of toxic effects. We investigated the potential of baru flour (Dipteryx alata) in mitigating t...
New RP-HPLC Method for Separation of Naja haje haje Venom and Studies of its Bactericidal Effect
New RP-HPLC Method for Separation of Naja haje haje Venom and Studies of its Bactericidal Effect
Abstract
Background: Snake venom is a complex mixture of biologically active substances. Some peptides and proteins from snake have already demonstrated their the...
The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice
The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice
Background: Hymenoptera venom allergy is an immunoglobulin (Ig) E mediated hypersensitivity reaction to Hymenoptera venoms. Obvious identification of the culprit insect that causes...

